CD30 ligand | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

2,645 results for “CD30 ligand”

Trials

View all 1314 →

CD30 CAR for CD30+ NSGCT

2 participants · First posted Dec 2, 2022

Active, not recruiting

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

38 participants · First posted Feb 24, 2016

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

20 participants · First posted Sep 10, 2019

Drugs

View all 775 →

Investigational

Recombinant CD40-ligand

CXCR4 (Ligand)

Mineralocorticoid Receptor Modulators (Ligand)

Organizations

View all 21 →

Ligand Pharmaceuticals

United States

CEL-SCI

United States

Eledon Pharmaceuticals

United States

News

View all 535 →

Merck Assumes Full Control of MK-8690 Anti-CD30 Ligand Antibody for Inflammatory Bowel Disease

Novel CAR-T Cell Therapy Shows 100% Response Rate in Refractory CD30+ Lymphoma Patients

Targeting CD30 in Diffuse Large B-Cell Lymphoma: Where Does It Fit in?

Page 1 of 265